{'fraction_non_alphanumeric': 0.02024584237165582, 'fraction_numerical': 0.008676789587852495, 'mean_word_length': 5.2342342342342345, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The role of androgen‐deprivation therapy on suicide among patients with advanced prostate cancer: A nationwide population‐based cohort study

Prostate cancer is the most common cancer among men with high annual mortality rates. Recent estimations revealed that there were 1.6 million incident cases of prostate cancer and 366 000 deaths in 2015, and it affects one in six men in highly developed countries. Prostate cancer is associated with risk of mental disorders. Depression and anxiety among men with prostate cancer, across the treatment spectrum, are common. Furthermore, population‐based studies have shown that men with prostate cancer are at an increased risk of death by suicide. Androgen‐deprivation therapy (ADT) as the form of chemical castration plays an integral part in the management of prostate cancer. ADT is commonly used for locally advanced and metastatic prostate cancer. In a recent meta‐analysis, a positive association between ADT and depression risk was demonstrated. Prostate cancer patients with depression may be at higher risk for completing suicide. Although previous studies have demonstrated an increased risk of suicide in prostate cancer patients, to our knowledge, the suicide in men treated with ADT has never been analysed. In this study, we aimed to explore whether suicide risk is affected by ADT among prostate cancer patients in Lithuania.